(Q45764586)

English

Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus

scientific article published in February 1997

In more languages

default values for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Effect of antiretroviral combination therapy (zidovudine/didanosine or zidovudine/lamivudine) on quantitative plasma human immunodeficiency virus-ribonucleic acid in children and adolescents infected with human immunodeficiency virus (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

author name string

Sölder B

1

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Wintergerst U

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Notheis G

3

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Eberle J

4

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Gürtler L

5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Belohradsky BH

6

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

language of work or name

0 references

publication date

1 February 1997

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

The Journal of Pediatrics

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

130

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

2

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

293-299

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Human immunodeficiency virus type 1 quantitative cell microculture as a measure of antiviral efficacy in a multicenter clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Multicenter evaluation of quantification methods for plasma human immunodeficiency virus type 1 RNA.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Evaluation of proviral copy number and plasma RNA level as early indicators of progression in HIV-1 infection: correlation with virological and immunological markers of disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Prediction of progression to AIDS with serum HIV-1 RNA and CD4 count

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Quantitation of human immunodeficiency virus by culture and polymerase chain reaction in response to didanosine after long-term therapy with zidovudine

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Treatment with lamivudine, zidovudine, or both in HIV-positive patients with 200 to 500 CD4+ cells per cubic millimeter. North American HIV Working Party

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Combination therapy with zidovudine and didanosine compared with zidovudine alone in HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Combination therapy with zidovudine and dideoxycytidine in patients with advanced human immunodeficiency virus infection. A phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Something better than zidovudine for children

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Decreased human immunodeficiency virus type 1 plasma viremia during antiretroviral therapy reflects downregulation of viral replication in lymphoid tissue

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Viral measurement by polymerase chain reaction-based assays in human immunodeficiency virus-infected infants

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Viral dynamics in human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Quantification of HIV-1 virus load under zidovudine therapy in patients with symptomatic HIV infection: relation to disease progression

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Evaluation of safety and efficacy of 3TC (lamivudine) in patients with asymptomatic or mildly symptomatic human immunodeficiency virus infection: a phase I/II study

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I/II study of 3TC (lamivudine) in HIV-positive, asymptomatic or mild AIDS-related complex patients: sustained reduction in viral markers. The Lamivudine European HIV Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS0022-3476%2897%2970358-5

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0022-3476(97)70358-5

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 December 2017

http://europepmc.org/abstract/MED/9042135

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q45764586&oldid=2081418338"